FDA Brief

Warning letters Drugs

FDA warning letter to

Aire-Master of America, Inc.

High riskIssued May 23, 2022Posted Jun 7, 2022Division of Pharmaceutical Quality Operations III

FDA cites Aire-Master of America for CGMP failures and unapproved, misbranded hand sanitizers made at its Missouri plant.

What happened

FDA inspected Aire-Master’s drug manufacturing facility in Nixa, Missouri, from October 5 to October 19, 2021. The inspection found CGMP violations in water system sampling and microbial testing, complaint investigation, release testing, cleaning of shared equipment, and component identity testing. FDA also reviewed hand sanitizer labels and found the products were unapproved new drugs and misbranded.

What FDA found

  1. The company’s water system sampling and microbial testing were not scientifically sound, and FDA samples from the water system were too numerous to count on multiple total microbial count tests.

    21 CFR 211.160(b)
  2. The company did not thoroughly investigate a customer complaint about a “fishy” odor in Foaming Waterless Hand Sanitizer lot #713588 and lacked meaningful corrective and preventive action.

    21 CFR 211.192
  3. The company released finished drug products without adequate testing for total microbial count and objectionable microorganisms.

    21 CFR 211.165(b)
  4. The company used the same equipment for household cleaners and topical OTC drugs without validating cleaning, so cross-contamination was not controlled.

    21 CFR 211.67(a)
  5. The company lacked a specific identity test for each lot of citric acid and carbomer and did not adequately test glycerin for diethylene glycol or ethanol for methanol.

    21 CFR 211.84(d)(1)
  6. The hand sanitizers were marketed as unapproved new drugs and were misbranded because they did not meet the conditions for marketing without an approved application.

    FD&C Act sections 505(a) and 502(ee), 21 U.S.C. 355(a) and 352(ee)

What FDA wants

FDA tells the company to provide comprehensive assessments and remediation plans for its water system, investigations/CAPA, laboratory testing, cleaning, and component testing, plus risk assessments and product testing. The provided letter text does not state a response deadline.

Who should pay attention

  • brands that buy OTC topical drugs from this manufacturer
  • consumers using ethanol-based hand sanitizers
  • drug manufacturers that share equipment with non-drug cleaners

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk